Erratum: Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: Post-hoc analysis of the Kremezin Study against renal disease progression in Korea (Kidney Res Clin Pract, (2017) 36, 1 (68-78), 10.23876/j.krcp.2017.36.1.68);Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: Post-hoc analysis of the kremezin study against renal disease progression in Korea

Kidney Research and Clinical Practice

Volumn 36, Issue 1, 2017, Pages 68-78

  Cha, Ran Hui ^a   Kang, Shin Wook ^b   Park, Cheol Whee ^c   Cha, Dae Ryong ^d   Na, Ki Young ^e,f   Kim, Sung Gyun ^g   Yoon, Sun Ae ^h   Kim, Sejoong ^e,f   Han, Sang Youb ⁱ   Park, Jung Hwan ^j   Chang, Jae Hyun ^k   Lim, Chun Soo ^f,l   Kim, Yon Su ^f,m  

^a National Medical Center   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

^g Hallym University   (South Korea)

^h The Catholic University of Korea   (South Korea)

ⁱ Inje University   (South Korea)

^j Konkuk University School of Medicine   (South Korea)

^k Gachon University College of Medicine   (South Korea)

^l Seoul National University Boramae Hospital   (South Korea)

^m Seoul National University   (South Korea)

more..

Author keywords

Advanced renal dysfunction; AST 120; Cardiovascular outcome; Renal outcome; Uremic toxin

Indexed keywords

AST 120; INDICAN; UREMIC TOXIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; INFORMED CONSENT; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOUTH KOREA; TREATMENT OUTCOME;

EID: 85034827920     PISSN: 22119132     EISSN: 22119140     Source Type: Journal    
DOI: 10.23876/j.krcp.2018.37.1.98     Document Type: Erratum

References (32)

1. Lee SW, Kim YC, Oh SW, Koo HS, Na KY, Chae DW, Kim S, Chin HJ: Trends in the prevalence of chronic kidney disease, other chronic diseases and health-related be-haviors in an adult Korean population: data from the Korean National Health and Nutrition Examination Survey (KNHANES). Nephrol Dial Transplant 26:3975-3980, 2011
2. ESRD Registry Committee, Korean Society of Nephrology: Current renal replacement therapy in Korea - Insan Memorial Dialysis Registry, 2015. The 36th Annual Meeting of the Korean Society of Nephrology, 2016, Seoul. Seoul: Korean Society of Nephrology, 2016
3. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
4. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R; RENAAL Study Investigators: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63:1499-1507, 2003
5. Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, Guo ZJ, Jiang JP: Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 18:1889-1898, 2007
6. Niwa T, Yazawa T, Maeda K, Ise M, Sugano M, Kodama T, Uehara Y: Effect of oral sorbent, AST-120, on serum concentration of indoxyl sulfate in uremic rats. Nihon Jinzo Gakkai Shi 32:695-701, 1990
7. Lin CJ, Chen HH, Pan CF, Chuang CK, Wang TJ, Sun FJ, Wu CJ: p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal 25:191-197, 2011
8. Atoh K, Itoh H, Haneda M: Serum indoxyl sulfate levels in patients with diabetic nephropathy: relation to renal function. Diabetes Res Clin Pract 83:220-226, 2009
9. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S: The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 62:S23-S28, 1997
10. Niwa T: The protein metabolite theory as a mechanism for the progression of renal failure. J Ren Nutr 11:181-182, 2001
11. Okada K, Takahashi S, Nagura Y, Hatano M, Shimamura T: Early morphological changes of tubules in rats with chronic renal failure. Nihon Jinzo Gakkai Shi 34:65-70, 1992
12. Miyazaki T, Aoyama I, Ise M, Seo H, Niwa T: An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrol Dial Transplant 15:1773-1781, 2000
13. Horike K, Usami T, Kamiya Y, Kamiya T, Yoshida A, Itoh S, Yamato H, Ise M, Kimura G: Oral carbonaceous absorbent modifies renal function of renal ablation model without affecting plasma renin-angiotensin system or protein intake. Clin Exp Nephrol 7:120-124, 2003
14. Takahashi N, Kawaguchi T, Suzuki T: Therapeutic effects of long-term administration of an oral adsorbent in patients with chronic renal failure: two-year study. Int J Urol 12:7-11, 2005
15. Sanaka T, Akizawa T, Koide K, Koshikawa S: Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy. Ther Apher Dial 8:232-240, 2004
16. Shoji T, Wada A, Inoue K, Hayashi D, Tomida K, Furumatsu Y, Kaneko T, Okada N, Fukuhara Y, Imai E, Tsubakihara Y: Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract 105:c99-c107, 2007
17. Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, Gejyo F, Matsuo S, Yorioka N, Kurokawa K; CAP-KD Study Group: Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 54:459-467, 2009
18. Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, Kato A, Shimizu M: Randomized placebo-controlled EPPIC trials of AST-120 in CKD. J Am Soc Nephrol 26:1732-1746, 2015
19. Cha RH, Kang SW, Park CW, Cha DR, Na KY, Kim SG, Yoon SA, Han SY, Chang JH, Park SK, Lim CS, Kim YS: A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction. Clin J Am Soc Nephrol 11:559-567, 2016
20. Owada S, Goto S, Bannai K, Hayashi H, Nishijima F, Niwa T: Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am J Nephrol 28:446-454, 2008
21. Gelasco AK, Raymond JR: Indoxyl sulfate induces complex redox alterations in mesangial cells. Am J Physiol Renal Physiol 290:F1551-F1558, 2006
22. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T: Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 63:1671-1680, 2003
23. Shimizu H, Bolati D, Adijiang A, Adelibieke Y, Muteliefu G, Enomoto A, Higashiyama Y, Higuchi Y, Nishijima F, Niwa T: Indoxyl sulfate downregulates renal expression of Klotho through production of ROS and activation of nuclear factor-kB. Am J Nephrol 33:319-324, 2011
24. Owada A, Nakao M, Koike J, Ujiie K, Tomita K, Shiigai T: Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int Suppl 63:S188-S190, 1997
25. Ueda S, Yamagishi S, Takeuchi M, Kohno K, Shibata R, Matsumoto Y, Kaneyuki U, Fujimura T, Hayashida A, Okuda S: Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med 12:180-184, 2006
26. Adijiang A, Niwa T: An oral sorbent, AST-120, increases Klotho expression and inhibits cell senescence in the kidney of uremic rats. Am J Nephrol 31:160-164, 2010
27. Maeda K, Hamada C, Hayashi T, Shou I, Wakabayashi M, Fukui M, Horikoshi S, Tomino Y: Long-term effects of the oral adsorbent, AST-120, in patients with chronic renal failure. J Int Med Res 37:205-213, 2009
28. Bohlender JM, Franke S, Stein G, Wolf G: Advanced gly-cation end products and the kidney. Am J Physiol Renal Physiol 289:F645-F659, 2005
29. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65:2309-2320, 2004
30. Goto S, Kitamura K, Kono K, Nakai K, Fujii H, Nishi S: Association between AST-120 and abdominal aortic calcification in predialysis patients with chronic kidney disease. Clin Exp Nephrol 17:365-371, 2013
31. Nakai K, Fujii H, Kono K, Goto S, Fukagawa M, Nishi S: Effects of AST-120 on left ventricular mass in predialysis patients. Am J Nephrol 33:218-223, 2011
32. Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Lang-ham RG, Nishijima F, Kelly DJ, Krum H: Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One 7:e41281, 2012